AstraZeneca plc vs Smith & Nephew plc: Which Is The Better Buy?

Should you add AstraZeneca plc (LON: AZN) or Smith & Nephew plc (LON: SN) to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today’s updates from AstraZeneca (LSE: AZN) (NYSE: AZN.US) and Smith & Nephew (LSE: SN) (NYSE: SNN.US) show that both companies are in the midst of transitional periods. So, while their respective performances in 2014 are perhaps not quite what their investors were hoping for, they both appear to be making strong progress towards improving profitability and delivering higher returns to shareholders.

However, if you could only buy one of the two, which should it be?

A Challenging 2014

2014 was a tough year for AstraZeneca, with the pharmaceutical company reporting core earnings per share (EPS) that were 15% down on their 2013 level, after its fourth-quarter EPS fell by 38%. This was largely due to the investments it is making in accelerating its existing portfolio of drugs and was made worse by currency headwinds which, when removed, gave figures of minus 8% and minus 28% respectively for the two periods. Still, it remains a severe decline and shows that the company has some way to go regarding a return to bottom line growth, which is expects to take place in 2017.

As such, AstraZeneca has agreed to buy the rights to Actavis’ North American respiratory business for $600m plus single-digit royalties above a specific revenue threshold. This will further enhance AstraZeneca’s respiratory division and broaden its product offering. It will also immediately add on-market revenues and contribute to the company’s financial performance.

Meanwhile, Smith & Nephew reported a rise in underlying revenue growth of just 2% in 2014, with its Advanced Wound Management division seeing its top line fall by 1%, due mainly to disappointing performance in the US. However, as a result of improving margins (trading margins rose by 0.2% in the year), adjusted EPS increased by 8.2% and, looking ahead, the company expects 2015 to be a year of faster revenue growth and further improvements to its trading profit, as its exposure to emerging markets in particular is set to deliver better performance for the company.

Looking Ahead

Although Smith & Nephew is performing better than AstraZeneca at the present time, as shown in today’s updates, both companies have considerable potential to improve their performance. However, when it comes to their valuations, AstraZeneca appears to appeal significantly more than Smith & Nephew, even when the latter’s stronger growth prospects over the next two years are taken into account.

For example, AstraZeneca trades on a forward price to earnings (P/E) ratio of 17.7 using 2016’s forecast earnings numbers. While not exactly cheap on an absolute basis, it appears to offer better value than Smith & Nephew, which has a forward P/E ratio of 18.2 using 2016 forecast earnings.

Furthermore, AstraZeneca has thus far delivered better performance than expected by many investors since its current management team took the reins in late 2012. Therefore, with the company having considerable financial firepower, it could be argued that its bottom line may improve at a faster rate than is currently being priced in, since further acquisitions could make a real difference to its earnings numbers.

As such, and while both stocks are worth buying at the present time, AstraZeneca’s better value and potential for a positive surprise regarding its forecasts make it the more appealing of the two companies – especially for longer term investors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

FTSE shares: the perfect ‘get rich slow’ idea?

As a long-term investor, Christopher Ruane reckons the FTSE 100 could offer him the foundations to create stock market wealth.…

Read more »

Investing Articles

Here’s how an investor in their 30s could aim to turn a £10k ISA into £132,676 by retirement

Christopher Ruane explains how someone with a 30-year investing timeframe could aim to increase an ISA stuffed with blue-chip shares…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have made a lot of investors very rich as they push to new heights. Dr James Fox explores…

Read more »

Investing Articles

£20k split between these 2 FTSE value stocks 1 month ago is now worth…

Harvey Jones has had his eye on two value stocks from the FTSE 100. Suddenly they've both taken off at…

Read more »

Investing Articles

Gold’s hit record highs – and these former penny shares have soared over 115%!

After gold recently hit record highs, it may be no surprise that two former penny shares focused on the yellow…

Read more »

Investing Articles

£20k in a Stocks and Shares ISA? Here’s how to target passive income of £633 a month

Christopher Ruane explains how an investor could turn a Stocks and Shares ISA into a passive income goldmine with a…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

How much passive income could I earn from dividends by investing £5,000 a year in the UK stock market?

When starting out it's often the first thing investors ask: how much passive income can I earn? Mark Hartley attempts…

Read more »

Young woman holding up three fingers
Investing Articles

3 steps to start investing with under £300

Christopher Ruane walks through a trio of steps that someone who wants to start investing with just a few hundred…

Read more »